Eton Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) just released its third-quarter report and things are looking bullish. Statutory revenue of US$58m and earnings of US$1.06 both blasted past expectations, beating expectations by 37% and 239%, respectively, ahead of expectations. Earnings are an important time for investors, as they can track a company’s performance, look at what the analysts are forecasting for next year, and see if there’s been a change in sentiment towards the company. We’ve gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

Following the latest results, Eton Pharmaceuticals’ four analysts are now forecasting revenues of US$266.4m in 2027. This would be a substantial 89% improvement in revenue compared to the last 12 months. Per-share earnings are expected to soar 55% to US$2.68. In the lead-up to this report, the analysts had been modelling revenues of US$220.4m and earnings per share (EPS) of US$2.10 in 2027. So we can see there’s been a pretty clear increase in sentiment following the latest results, with both revenues and earnings per share receiving a decent lift in the latest estimates.

Check out our latest analysis for Eton Pharmaceuticals

With these upgrades, we’re not surprised to see that the analysts have lifted their price target 9.1% to US$78.00per share. There’s another way to think about price targets though, and that’s to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. Currently, the most bullish analyst values Eton Pharmaceuticals at US$82.00 per share, while the most bearish prices it at US$70.00. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The analysts are definitely expecting Eton Pharmaceuticals’ growth to accelerate, with the forecast 66% annualised growth to the end of 2027 ranking favourably alongside historical growth of 42% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 8.5% per year. Factoring in the forecast acceleration in revenue, it’s pretty clear that Eton Pharmaceuticals is expected to grow much faster than its industry.

The Bottom Line

The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Eton Pharmaceuticals’ earnings potential next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates – from multiple Eton Pharmaceuticals analysts – going out to 2028, and you can see them free on our platform here.

It is also worth noting that we have found 3 warning signs for Eton Pharmaceuticals (2 can’t be ignored!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.